BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

BridgeBio Pharma (BBIO) will present acoramidis and ATTR-CM research at the American Heart Association Scientific Sessions on November 6–9, 2026.

Rhea-AI Summary

BridgeBio Pharma (BBIO) will present acoramidis and ATTR-CM research at the American Heart Association Scientific Sessions on November 6–9, 2026. The Chicago meeting will feature two moderated posters, three posters and one Abbott Laboratories-led, BridgeBio-supported poster.

Presentations include analyses from ATTRibute-CM examining heart failure events, repeated cardiovascular hospitalizations and mortality, and recovery after cardiovascular hospitalization. Other presentations address screening and detection of transthyretin amyloid cardiomyopathy (ATTR-CM) and laboratory detection of transthyretin. No numerical findings from these presentations are disclosed.

Key Terms

nt-probnp, transthyretin

2 terms

nt-probnp medical

"N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis"

A blood test marker released when the heart is under strain; higher NT‑proBNP levels indicate the heart is working harder or may be failing, similar to a dashboard warning light that signals engine stress. Investors watch NT‑proBNP because changes in the marker can drive clinical trial results, treatment approvals, hospital use, and insurance decisions for heart drugs and devices, all of which affect revenue, adoption and valuation in healthcare companies.

transthyretin medical

"transthyretin (TTR) stabilizer"

Transthyretin is a protein made in the liver that normally carries the thyroid hormone and vitamin A in the blood; think of it as a delivery truck moving small molecules around the body. It matters to investors because when transthyretin misfolds and clumps together it can cause progressive heart and nerve disease, creating demand for diagnostics, medicines and tests—so developments around this protein can move markets for healthcare and biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA), and the Australian Therapeutic Goods Administration (TGA) with all labels specifying near-complete stabilization of TTR.

Moderated Posters:
Bridging the Diagnostic Gap in Transthyretin Cardiac Amyloidosis (ATTR-CM): Enhancing ATTR-CM Detection at the Time of Heart Failure Diagnosis in Women Through Sex-Specific ATTR Models (SS-ATTR-CMs)
Presenter: Hyewon Jeong, M.D., M.S., Massachusetts Institute of Technology, U.S.
Date/time: Monday, November 9 at 9:50 am CT

Artificial Intelligence for the Screening of ATTR Cardiomyopathy in the U.S.: A Multicenter Analysis from the TRACE-AI Network
Presenter: Bruno Batinica, MBChB, Yale School of Medicine, U.S.
Date/time: Monday, November 9 at 11:20 am CT

Posters:
Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Mazen Hanna, M.D., Cleveland Clinic, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Findings from ATTRibute-CM Using Multistate Modeling
Presenter: Justin L. Grodin, M.D., UT Southwestern Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Recovery After Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from an N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis of the ATTRibute-CM Study
Presenter: Prem Soman, M.D., University of Pittsburgh Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Abbott Laboratories-Led, BridgeBio-Supported Poster Presentation:
Detection of Tetrameric Transthyretin by ARCHITECT c and Alinity c Assays
Presenter: Lici A. Schurig Briccio, Ph.D., Abbott Laboratories, U.S.
Date/time: Monday, November 9 at 9:36 am CT

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
BridgeBio Investor Relations
ir@bridgebio.com